Accès ouvert
2025
article
OpenAlex
Oscar C. Y. Yang, Yi‐Hao Chiang, Caleb Gon‐Shen Chen, Yu‐Cheng Chang et autres
BACKGROUND: Daratumumab represents the first-in-class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM). Evidence from randomized controlled trials has shown daratumumab to be efficacious in the setting of second-line combinational therapy for pretreated multiple myeloma. …
tw
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Alberto Carturan, Mathew G. Angelos, Puneeth Guruprasad, Ruchi P. Patel et autres
ABSTRACT Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chimeric antigen receptor (CAR) T-cells against T-cell neoplasms is limited by a lack …
us, tw, cn, it
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Yi‐Hao Chiang et autres
Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have …
us, tw, hk, cn, kr, it
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Chi Wang, Nai-Wen Su, Kate Hsu, Chen-Wei Kao et autres
BACKGROUND: Despite the advances of therapies, multiple myeloma (MM) remains an incurable hematological cancer that most patients experience relapse. Tumor angiogenesis is strongly correlated with cancer relapse. Human leukocyte antigen G (HLA-G) has been known as a molecule to suppress angiogenesis. We …
tw
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Yi‐Hao Chiang, Ching-Ting Lien, Wen-Hao Su, Tsung-Yu Yen et autres
BACKGROUND: Clinical evidence for the rapidity and effectiveness of fentanyl buccal soluble film (FBSF) in reducing pain intensity of breakthrough cancer pain (BTcP) remains inadequate. This study aimed to evaluate the efficacy of FBSF proportional to the around-the-clock (ATC) opioid regimens in …
tw
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Mathew G. Angelos, Ruchi P. Patel, Yi‐Hao Chiang, Wei‐Fen Xie et autres
T cell neoplasms, such as peripheral T cell lymphomas (PTCL) and acute T cell lymphoblastic leukemia (T-ALL), have some of the worst prognoses of all hematological malignancies. Poor outcomes are driven by a limited number of effective treatments, particularly in relapsed and …
us, it
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Yu‐Cheng Chang, Yi‐Hao Chiang, Kate Hsu, Chih‐Kuang Chuang et autres
Abstract Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (γδT) cells possess the potent anticancer capability, here we investigated the potential involvement …
tw
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Ken‐Hong Lim, Jo-Ning Wu, To‐Yu Huang, Jie‐Yang Jhuang et autres
][6] KIT D816V mutation can be detected in .90% of SM patients. 7Interestingly, multilineage involvement of KIT D816V and multimutations in other genes such as SRSF2, ASXL1, and RUNX1 are frequently detected in advSM. 8[12] Recently, the multikinase inhibitor midostaurin was approved …
tw, us
(code pays fourni par la source)
2020
article
OpenAlex
Inkook Chun, Ki Hyun Kim, Yi‐Hao Chiang, Wei‐Fen Xie et autres
Chimeric Antigen Receptor T cells (CART) have led to unprecedented clinical responses in relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma. However, despite these exciting results, most patients treated with CART therapy either do not …
us, tw
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Ken‐Hong Lim, Yu‐Cheng Chang, Yi‐Hao Chiang, Huan‐Chau Lin et autres
Background: Calreticulin (CALR) mutations are one of the major driver mutations in BCL-ABL1-negative myeloproliferative neoplasm (MPN) and are frequently detected in JAK2/MPL-unmutated essential thrombocythemia and primary myelofibrosis. Mutant CALR activates JAK-STAT signaling through an MPL-dependent mechanism to mediate pathogenic thrombopoiesis in MPNs. …
tw
(code pays fourni par la source)
2018
conference-abstract
OpenAlex
Yi‐Hao Chiang, Yu‐Cheng Chang, Huan‐Chau Lin, Ling Huang et autres
Abstract Background: Essential thrombocythemia (ET) is a BCL-ABL1-negative myeloproliferative neoplasm characterized by increased number of mature megakaryocytes in the bone marrow and sustained thrombocytosis in the peripheral blood. ET is associated with an increased risk of hemorrhagic and thrombotic complications and leukemic …
tw
(code pays fourni par la source)
Accès ouvert
2017
article
OpenAlex
Yi‐Hao Chiang, Yu‐Cheng Chang, Huan‐Chau Lin, Ling Huang et autres
// Yi-Hao Chiang 1, 2, * , Yu-Cheng Chang 1, 2, 3 * , Huan-Chau Lin 1, 2 , Ling Huang 2 , Chun-Chia Cheng 1, 2 , Wei-Ting Wang 1 , Hung-I Cheng 4 , Nai-Wen Su 1, 2, 3 , …
tw
(code pays fourni par la source)